Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXY-059 in Acute Intracerebral Hemorrhage
NCT00075959Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OKN-007 in intracerebral hemorrhage (ICH) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and Tolerability and modified Rankin Scale at 90 days. Started Aug 2004; status: completed.
02
Drugs
OKN-007
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT00075959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075959.